Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial

  1. Tahanan
  2. Pandaigdig
  3. USA
  4. Austin
  5. Negosyo (B2B)
  6. Mga Negosyo na Ibinebenta
  1. Posted by: [email protected]
  2. Member since: June 2026
  3. Posted:
  4. Kategorya: Mga Negosyo na Ibinebenta
  5. Rehiyon: Austin (Astin)
  6. ID ng Paskil: 63684214
Genentech’s Phase III Krascendo 1 trial shows divarasib significantly improves progression-free survival over approved KRAS G12C inhibitors in advanced NSCLC patients.

Austin, Businesses For Sale, Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial
BumAlik Next
I-email sa Kaibigan

Ask AI to Review This Ad

Problema sa patalastas na ito?


How to Avoid Scams